{"ticker": {"uuid": "c1c50c89-31ce-4299-b83b-1107b066ba4d", "symbol": "BNTX", "name": "BioNTech SE", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "BioNTech: The Market Is Paying Too Much For An Unproven Pipeline (NASDAQ:BNTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQZEpOTTk4bVhjb3NwM1E3c2tPSDZJN1VQUGFlTFBXUVczX1hQSjJhOEpjRk5CNE5MTVNLSzQwUmlzUG5IT08tQW9yOWFWcHV6emZFR3EyV1JBTDNCS0NHa3JHdmZuOXl4VHc4VlkyUEVkRFM2Q1NEel8xbkZUZFBYTXVUYXVXU3JkNXpkYnZnYlZVejR2UlV4SWZDSXJtMWoxSERoWjhkRQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-21T16:30:08+00:00", "published_display": "21 Jul 2026 16:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioNTech to Report Second Quarter 2026 Financial Results on August 4, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPaHdVbUkyeTd4anRvS3l1bUNnSExSZUxvUFNRREVKWTJPY1ZKX2phZXk5MEhRWE5aX0FTTkhvUkVJQ0lwWktrYUNmVnlmZVA2MjRXaGZSWTlnUWxtcWdhTmt5bGdpYmZENVhJMHE5RFgweldUT1Z6SERjRnNZeEFTVGVlTXZGbkJWLUZUYUF1VmpOenBhalFud0FPMC04U1BSMHZCYWJQM1Z2d1pmQUE?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-21T10:50:00+00:00", "published_display": "21 Jul 2026 10:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026", "summary": "BioNTech SE is scheduled to announce its second-quarter 2026 financial results on Tuesday, August 4, 2026. The company will also host a conference call and webcast on the same day at 8:00 a.m. ET to discuss the results and provide a corporate update. Investors and the public can ", "url": "https://www.manilatimes.net/2026/07/21/tmt-newswire/globenewswire/biontech-to-report-second-quarter-2026-financial-results-and-corporate-update-on-august-4-2026/2388277/amp", "source_name": "The Manila Times", "published_at": "2026-07-21T11:10:03", "published_display": "21 Jul 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioNTech sets Aug. 4 webcast for second-quarter update", "summary": "BioNTech SE (Nasdaq: BNTX) announced it will release its second-quarter 2026 financial results on Tuesday, August 4, 2026. On the same day, the company will host a conference call and webcast at 8:00 a.m. ET (2:00 p.m. CET) to discuss the results and provide a corporate update. I", "url": "https://www.stocktitan.net/news/BNTX/bio-n-tech-to-report-second-quarter-2026-financial-results-and-92avg8u2kvau.html", "source_name": "Stock Titan", "published_at": "2026-07-21T11:10:03", "published_display": "21 Jul 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioNTech SE (0A3M) to Announce Q2 2026 Financial Results and Host Investor Call on August 4", "summary": "BioNTech SE (Nasdaq: BNTX, 0A3M), a biopharmaceutical company, announced it will release its second-quarter 2026 financial results on Tuesday, August 4, 2026. Concurrently, the company will host a live conference call and webcast at 8:00 a.m. ET (2:00 p.m. CET) to discuss its qua", "url": "https://kalkinemedia.com/uk/news/announcements/biontech-se-0a3m-to-announce-q2-2026-financial-results-and-host-investor-call-on-august-4", "source_name": "Kalkine Media", "published_at": "2026-07-21T11:10:03", "published_display": "21 Jul 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "German biotech company behind COVID-19 vaccine took its first steps with help from the ERDF", "summary": "BioNTech, the German biotechnology company behind the Pfizer COVID-19 vaccine, received crucial early support from the European Regional Development Fund (ERDF) in 2009. This funding, totaling EUR 2.2 million, enabled the company to expand its research and development infrastruct", "url": "https://ec.europa.eu/regional_policy/projects/projects-database/german-biotech-company-behind-covid-19-vaccine-took-its-first-steps-with-help-from-the-erdf_en", "source_name": "European Commission", "published_at": "2026-07-19T19:13:12", "published_display": "19 Jul 2026 19:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioNTech (BNTX) Faces Fresh Patent Lawsuits, Is The Valuation Gap Too Wide?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-19T06:31:44+00:00", "published_display": "19 Jul 2026 06:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Pfizer-BioNTech COVID-19 Vaccine. Updated formulation keeps Comirnaty relevant", "summary": "The Pfizer-BioNTech COVID-19 Vaccine (Comirnaty) continues to be a key product for Pfizer, with updated formulations targeting current SARS-CoV-2 variants. The article details its development, regulatory approvals for various age groups, manufacturing and distribution challenges ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/the-pfizer-biontech-covid-19-vaccine-updated-formulation-keeps-comirnaty/69796860", "source_name": "ad-hoc-news.de", "published_at": "2026-07-18T14:58:45", "published_display": "18 Jul 2026 14:58", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors Are Reacting To BioNTech (BNTX) Expanded Global Patent Suits Targeting Its mRNA COVID-19 Vaccines", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-18T01:37:34+00:00", "published_display": "18 Jul 2026 01:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The BNT162b2 mRNA COVID-19 vaccine. Regulatory milestones shape BioNTech\u2019s core product", "summary": "BioNTech's BNT162b2 mRNA COVID-19 vaccine has evolved from emergency use to full approval in key markets, serving as both a primary and booster immunization. This product is a crucial driver for BioNTech's stock performance and forms the foundation for its broader mRNA portfolio,", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/the-bnt162b2-mrna-covid-19-vaccine-regulatory-milestones-shape/69785732", "source_name": "Ad Hoc News", "published_at": "2026-07-17T07:10:46", "published_display": "17 Jul 2026 07:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Arbutus Biopharma, Genevant sue Pfizer, BioNTech Over Lipid Nanoparticle Patents", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/arbutus-biopharma-genevant-sue-pfizer-121613854.html", "source_name": "MT Newswires", "published_at": "2026-07-16T12:16:13+00:00", "published_display": "16 Jul 2026 12:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders", "summary": "Arbutus Biopharma, and its licensee Genevant, have initiated three international lawsuits against Pfizer and BioNTech for patent infringement related to their LNP technology used in COVID-19 vaccines. Arbutus has also received approximately $178 million from Moderna as part of a ", "url": "https://finance.yahoo.com/healthcare/articles/arbutus-initiates-international-patent-infringement-113000295.html", "source_name": "Market source", "published_at": "2026-07-16T11:41:56", "published_display": "16 Jul 2026 11:41", "sentiment": "negative", "sentiment_pct": 35, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The BNT162b2 COVID-19 Vaccine - BioNTech bets on updated protection", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQUFk5VjdYSHZ6MUhhNmYwNmFFRklWd0h0OVJqS08zNWY2NnFVTDVBaEJibWJNRFlteEtsSlo0LTBDX3NoSmZQMmhmUjBlVjhfZkR1anpBcHE0RVJJOXpNZkRfaE82UDAtY0YxMEs5M1VsM2Nwa3FjR3VMcWhVZkVWS3BBdm94ZmdHaUYzM3VkbDJ3Vmh1RC0xYWdqYjFDLXliOFhYdFVDVkVBbXMwaTB4OUNXQ0pxNHhXZmNxclJHOHNtQQ?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-16T10:34:50+00:00", "published_display": "16 Jul 2026 10:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(BNTX) as a Liquidity Pulse for Institutional Tactics", "summary": "This article provides an AI-driven analysis of BioNTech SE (NASDAQ: BNTX), highlighting a near-term weak sentiment that may lead to a resumption of long-term weakness. It details three institutional trading strategies\u2014Position Trading, Momentum Breakout, and Risk Hedging\u2014with spe", "url": "https://news.stocktradersdaily.com/news_release/16/BNTX_as_a_Liquidity_Pulse_for_Institutional_Tactics_071626040202_1784188922.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-16T03:41:57", "published_display": "16 Jul 2026 03:41", "sentiment": "negative", "sentiment_pct": 35, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cathie Wood's Ark Invest Sold $7.4 Million of BioNTech Stock", "summary": "Cathie Wood's Ark Invest recently sold over $7.4 million worth of BioNTech stock from its Ark Genomic Revolution ETF, leaving it with a minimal holding. This divestment follows BioNTech's underperformance, projected revenue decline due to reduced COVID-19 vaccine sales, consecuti", "url": "https://finance.yahoo.com/markets/stocks/articles/cathie-woods-ark-invest-sold-140200626.html", "source_name": "Market source", "published_at": "2026-07-14T14:02:02", "published_display": "14 Jul 2026 14:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "The BNT162b2 vaccine - BioNTech SE bets on mRNA staying power", "summary": "BioNTech's BNT162b2 mRNA vaccine, co-developed with Pfizer, continues to be a cornerstone of the company's infectious disease portfolio, driving its stock price. The article highlights the vaccine's global reach, complex logistics, and evolving formulations targeting new variants", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/the-bnt162b2-vaccine-biontech-se-bets-on-mrna-staying-power/69758817", "source_name": "ad-hoc-news.de", "published_at": "2026-07-13T07:11:37", "published_display": "13 Jul 2026 07:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioNTech\u2019s Triple Transformation: Shuttering Plants, Losing Founders, and Banking on 15 Cancer Trials", "summary": "BioNTech is undergoing a significant corporate transformation, closing manufacturing plants and winding down a subsidiary, resulting in approximately 2,000 job cuts. This restructuring is occurring as the company's founders, Ugur Sahin and \u00d6zlem T\u00fcreci, prepare to depart to pursu", "url": "https://www.aktiencheck.de/news/Artikel-BioNTech_s_Triple_Transformation_Shuttering_Plants_Losing_Founders_and_Banking_on_15_Cancer_Trials-19923779", "source_name": "aktiencheck.de", "published_at": "2026-07-11T08:10:13", "published_display": "11 Jul 2026 08:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is BioNTech (BNTX) Undervalued As It Exits German Manufacturing Sites?", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/biontech-bntx-undervalued-exits-german-211008667.html", "source_name": "Simply Wall St.", "published_at": "2026-07-10T21:10:08+00:00", "published_display": "10 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioNTech (BNTX) Stock Could Be Overvalued After a 58% Five Year Slump", "summary": "BioNTech's stock has declined 57.5% over the past five years and is currently screening as overvalued based on market multiples, particularly its Price/Sales ratio of 7.3x compared to a fair implied P/S of 5.3x. Despite ongoing plans to reduce costs by exiting German manufacturin", "url": "https://finance.yahoo.com/markets/stocks/articles/biontech-bntx-stock-could-overvalued-121542659.html", "source_name": "Market source", "published_at": "2026-07-10T05:15:00", "published_display": "10 Jul 2026 05:15", "sentiment": "negative", "sentiment_pct": 27, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cathie Wood\u2019s ARK sells BioNTech and buys SpaceX stock", "summary": "Cathie Wood's ARK ETFs engaged in significant trading activity on July 8th, 2026. The firm sold over 78,000 shares of BioNTech and continued its trend of selling Roku and Advanced Micro Devices stock. Conversely, ARK made a substantial purchase of over 181,000 shares of Space Exp", "url": "https://www.investing.com/news/company-news/cathie-woods-ark-sells-biontech-and-buys-spacex-stock-93CH-4782834", "source_name": "Investing.com", "published_at": "2026-07-09T00:03:14", "published_display": "09 Jul 2026 00:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janet Markman: Excited to Become Director of Translational Sciences Oncology at BioNTech", "summary": "Janet Markman has been promoted to Director of Translational Sciences Oncology at BioNTech SE. She expressed her excitement and gratitude for the support and collaboration of her teams, acknowledging their role in her personal and professional growth. Markman is looking forward t", "url": "https://oncodaily.com/career/janet-markman-537837", "source_name": "Oncodaily", "published_at": "2026-07-08T14:41:14", "published_display": "08 Jul 2026 14:41", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioNTech SE strengthens its mRNA pipeline as investors watch global demand", "summary": "BioNTech SE is expanding its mRNA pipeline, focusing on oncology and infectious diseases, beyond its prominent COVID-19 vaccine success. The company aims to convert its scientific platform into sustainable revenue through various cancer vaccine approaches and strategic collaborat", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/biontech-se-strengthens-its-mrna-pipeline-as-investors-watch-global-demand/69717596", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T22:28:00", "published_display": "07 Jul 2026 22:28", "sentiment": "positive", "sentiment_pct": 69, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of BioNTech SE \u2013 NASDAQ:BNTX", "summary": "This article provides financial data for BioNTech SE (NASDAQ: BNTX), specifically its enterprise value to EBIT forward. It notes that the market for BNTX was closed with no trades. The information is presented by TradingView, sourcing data from ICE Data Services and FactSet Resea", "url": "https://www.tradingview.com/symbols/NASDAQ-BNTX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T11:39:01", "published_display": "04 Jul 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioNTech stock weighs pipeline and cash runway", "summary": "BioNTech's stock performance is heavily influenced by its clinical pipeline, partnership model, and the cash reserves accumulated from its COVID-19 vaccine sales. The company's ability to advance late-stage programs while maintaining significant R&D investment is crucial for its ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/biontech-stock-weighs-pipeline-and-cash-runway/69683070", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T20:41:07", "published_display": "03 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioNTech price exposed to negative pressures - Forecast today - 01-07-2026", "summary": "BioNTech SE (BNTX) experienced a decline in intraday trading due to resistance at its 50-day Simple Moving Average and extremely overbought momentum indicators. The primary short-term bearish trend remains dominant, and the forecast predicts further downside toward the $85.00 sup", "url": "https://www.economies.com/stocks/united-states-analysis/biontech-price-exposed-to-negative-pressures---forecast-today---01-07-2026-128122", "source_name": "Economies.com", "published_at": "2026-07-01T12:09:07", "published_display": "01 Jul 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioNTech SE (BNTX) Investor Outlook: Potential Upside of 33.49% Amidst Revenue Challenges", "summary": "BioNTech SE (BNTX) shows a potential upside of 33.49% with an average target price of $121.77, despite facing challenges such as negative revenue growth (-35.40%) and negative earnings per share. The company's robust pipeline in oncology and infectious diseases, particularly adva", "url": "https://www.directorstalkinterviews.com/biontech-se-bntx-investor-outlook-potential-upside-of-33-49-amidst-revenue-challenges/4121254952", "source_name": "DirectorsTalk Interviews", "published_at": "2026-06-29T10:11:00", "published_display": "29 Jun 2026 10:11", "sentiment": "positive", "sentiment_pct": 59, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vikas Sehdev: Starting a New Chapter as Senior Medical Science Liaison at BioNTech SE", "summary": "Vikas Sehdev has announced his departure from AstraZeneca after five years to join BioNTech SE as a Senior Medical Science Liaison focusing on Breast Cancer. He expressed gratitude for his time at AstraZeneca and enthusiasm for BioNTech's commitment to pioneering innovative thera", "url": "https://oncodaily.com/career/vikas-sehdev-530153", "source_name": "Oncodaily", "published_at": "2026-06-28T06:39:40", "published_display": "28 Jun 2026 06:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of BioNTech SE Sponsored ADR \u2013 BSESOF:22UA", "summary": "This article provides financial data for BioNTech SE Sponsored ADR (BSESOF:22UA) on TradingView, specifically focusing on its enterprise value to forward revenue. It presents a concise overview of the company's financial performance metrics for investors and analysts using the pl", "url": "https://www.tradingview.com/symbols/BSESOF-22UA/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T19:39:40", "published_display": "27 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioNTech SE Sponsored ADR Actuals & Estimates (NASDAQ:BNTX)", "summary": "This page on TradingView provides financial actuals and estimates for BioNTech SE (NASDAQ:BNTX). Users can explore reported financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation metrics, comparing actual results with av", "url": "https://www.tradingview.com/symbols/NASDAQ-BNTX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T17:10:35", "published_display": "27 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of BioNTech SE \u2013 NASDAQ:BNTX", "summary": "The article provides a financial metric, the \"Price to sales forward,\" for BioNTech SE (NASDAQ: BNTX). It presents a data table with \"Period,\" \"Value,\" \"Change,\" and \"Change %\" for this metric. The content highlights that the market was closed at the time of viewing, with no trad", "url": "https://www.tradingview.com/symbols/NASDAQ-BNTX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T11:10:35", "published_display": "27 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioNTech (BNTX) director Susanne Schaffert files Form 3 ownership", "summary": "BioNTech director Susanne Schaffert has filed a Form 3, an initial statement of beneficial ownership, identifying her as a director of BioNTech SE. This filing does not indicate any stock purchases, sales, or other share transactions, establishing a baseline of her holdings. The ", "url": "https://www.stocktitan.net/sec-filings/BNTX/form-3-bio-n-tech-se-initial-statement-of-beneficial-ownership-eb3813d8b73f.html", "source_name": "Stock Titan", "published_at": "2026-06-26T13:39:41", "published_display": "26 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioNTech (BNTX) director Low-Friedrich files Form 3 with no trades", "summary": "BioNTech director Iris Katharina Low-Friedrich has filed an initial Form 3, indicating her new director status at the company. The filing, however, reports no insider transactions or holdings, meaning there were no purchases, sales, or derivative securities beneficially owned at ", "url": "https://www.stocktitan.net/sec-filings/BNTX/form-3-bio-n-tech-se-initial-statement-of-beneficial-ownership-346e00ee72ae.html", "source_name": "Stock Titan", "published_at": "2026-06-26T13:39:41", "published_display": "26 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of BioNTech SE Sponsored ADR \u2013 BSESOF:22UA", "summary": "This article displays the \"Enterprise value to EBIT forward\" for BioNTech SE Sponsored ADR (BSESOF:22UA) on TradingView. It appears to be a stub or data point from a financial platform, showing that the market was closed at the time and no trades were recorded for this metric. Th", "url": "https://www.tradingview.com/symbols/BSESOF-22UA/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T11:39:41", "published_display": "26 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is BioNTech SE (BNTX) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPLVdXU1ZUU0l5OHQ2alNDMlMzZ1FmV1o4ZVl2emdyTTNiNEpLdHFsRzlBeml5V213ZG1BYkNhMl9CbDFrWF9jNWxEaVJ6Z2luQ1pBcEdtLVk1dHBoTmhUQzlRT0NJaHpwX3phc3F2UnZQRnhSU055UE5JUXIxWGN4bWMzOXZwSGUxVTlSRG8zMGo2aDdFZmZn?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioNTech (BNTX) and Bristol Myers Share New Results From ROSETTA Lung-02 Study", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNRk95NUc5WnY3OGZ0ZGlERk1CQkdBTnNkV1dLeUZvS08tM19UMTl6eHJDelRrcVF6aFFSRGJTNUNMUkZadDhOQnJ5WGtKU05wQmFrUTV0V1FqS0x6UEZlNmFORGlEd1ZXdDBOd0M0dnlianRWcFRoYUk5Y1YxbXhUMFZJWXYyWmhQeEJ6RGRNN3hpb1RPMEhZRlNEZW94eUk5aEpwSw?oc=5", "source_name": "Market source", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing BioNTech (BNTX) Valuation After Recent Share Price Weakness And Conflicting Growth Signals", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOYnBVSHhrVWxESEU5SlFmZmJ6cGhnNjBwVldSZnRUOXZZNTV4TDRSOXJHREM0TXR5dzhyd1pSVmZiVUh6aUxLZVI0R2pjRDJ6R1VwQUxnUDFFRjA0cTJKcTQ4YkgwUDZBazU1RjVaSjZ3OEZLUjVKUVhQblY3Q2Z3X3RMTDRoR1dYMTdzdzhoLUl4UXlLUm8zMkc1UUVrdGZSZXpYOVBnTkI?oc=5", "source_name": "Market source", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioNTech (BNTX) sets up USD 1.0B Nasdaq ADS repurchase program", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQYXhjMlNpUEpwdEduVmlNb2E0TGFsYXViZEYtVkFiUWprV0d6Ul91MFpPZXdNcUFRSXNyYXE2LWExWHU1THJXWDdzY2h3VHg2YjVIRVVUMXZxR3pCbUpmY2MxWGhiOGREYUdXekg4VDF6bVNPWnZmQXpiWGsxWUR0WHIzcVhuU3ZvQ1RvVHpWV29CcDc5dmFpRzNlajdtdVpLOGpHYXZRUkp3QUVFTHc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioNTech Stock Forecast | ASCO Oncology Data Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxQQThIWUU1Wm9DMWQ3eTJBeGFfYkoxMjZKUHFwdFdma3h1MW5DVnpuSEU1ckxhUU1rLTN0eFQzZG1yQ1NkOUN6b2txaUxGVWZiU3RLX0ZRelNBV2RBNDBDU0g2d3RpMGVZVEFpRFNKbHN4eDNxdkRxV0lrbjJTZWlOM19n?oc=5", "source_name": "Capital.com", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Experimental BioNTech lung cancer drug shows high responses in early trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOWHc1SXBERm82bTlyLXA4NTdQVWdobVljbGlQbm53aVVZVmJkRkhoeUZSR01xUmhtNjlEVVE1OXZHTS1wcmpHZ3hkcmFpaUJOQ0pXMWhfcjJsS2h2eXUtTWRjMDV2ZHJzOFlDajMyWE1pMjVpV25ITWh2bFphcHBlZGprWmR1dmdWb1BsRlZsYUJaaEJ6Qk1sQ1hKWUF2UUx3X0ptWGJJLVpxeHhwUHpmSG9UekJhNTRqbE9sa1NOVQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-30T07:00:00+00:00", "published_display": "30 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "$1B BioNTech buyback runs to 2027 as company taps cash reserves", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQOHVHVDVBaU1mMmUtX2xGbXpQcnRnblktNzhURm1ONFcyRTF2bzRvMzdJTFFGcHlHMzZwUjhKM3pPUVhyM3dNZE90M3FNcUItd3dYRVFPSFktcVZ0eDZ4dVlUbXZVSWI2cXo4MkhSU0laVkJfWWFPbHk2am5UdzJYUWtRWkpneldZRGt5Rlg5Q3lUWWxfMXV3RTZB?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioNTech Q3 Earnings Review: Getting Into The Weeds With Bewildering Oncology Plans", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQcUxGa3RyTFlOTGNncnItMU5aMGhwNkFLWWxKMW9jeEJTSTVwLUJ3MzBwZTBwbk9nekxNYVVhNTQ2M2NMRzI5Q2xQS21KT0lzdUM5emRubkNJNkV4Smt4a2Rpd2Z6T0pWSjJtU2xiV0ZnWFdsaGYtSl83OWMtOWFEa2JFT3lZVHpQYTN6c1JpRWF4R3JwMWhyZkpQLWFFLW91X2xjMVlJZDV2SmN1YlBHZVBGblZienJlTTRmQzlRSXI?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BNTX Stock News: BioNTech Announces Layoffs as Covid-19 Revenue Slides", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNanFBQ290LVQ1eWhJUmE3TDI0RDJWTWgyeVRiV25nZncyekVKdnpIamhiMndBN2pySEF0LThuQnJDNTNHRy1EV01IREpZbTY3Z3kzb2NnU2xTaWVqU3VIbjNhOUhVdmlaSUtoSGUtNjB1NFFrTkpzTm5pYVd4TnRBMThXZjlKVXNMYmxaTDQzRloxVFRfbGNnejkxcHc5OE5B?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioNTech price receives positive push - Forecast today - 05-05-2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOOV9KWUJWZnpNdjNZT3ZjajBrMnV5MS1ENExTdXhGbGFJbTJWV3N1ZDBfcUZQalZabTBYdmVYUTFvNUJCX1B0eVZfaUgzZzhVSkd4RXJrdUFvWjh2MjhnWHc0ZmJYNDdYeS1qMVlJcFREV2xxbnJDSjIydldjZ05GSXROYkVMSmdQZ2lEbDhkM2R2MTZJY2gzcW9nbmhwOVpGSUVDZlVtM1h1SXdBbjlISEk5OUF6OWdUa1BLcnFBWUc0VnNheWQtekFB?oc=5", "source_name": "Economies.com", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "BioNTech (BNTX) Surges 6.1%: Is This an Indication of Further Gains?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxNWXhmaDZkdDJ4Ti1WSG9ReFZwT2JYX2xaVkFjQmNSRWhSakk2aTNtV1FsYXF6OENmRURlaTdfcURzREdNSDRnMXAzcVdWcmpIQjZvZDFsSEs3YS0zaVlRSHFJckNLZFF5QTZ3Ym9NRG1hTFE4LU1jSEMxcTZVZC1Ib2tvb2YzZFlmRzdtak11STZsREE?oc=5", "source_name": "Market source", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Analysts Offer Insights on Healthcare Companies: Teleflex (TFX), Cigna (CI) and BioNTech SE (BNTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxNUVoyWXU2STdaQTRoeXNTZ2NoRG5TOElMQ3BZSjBfQ0J2SnNCU01jdXNFSDZuMXVNV3hlOVVKeHpxaDVKejZpUklzbE5UZnBjcUxCb080dHlueVpQRTNxX3FZR3NUTnhlbEtMWU91b1ZGZFRYbGZmdkR5NTJrQU9jUmxzYzg0dlJsaEQ0eDktWUJhRE1CeXhTWUVVY200SGF4a0tyTnhUTEhDcm9sVFZhODd3ckUzc0xUcjkyT3ExeW5udTJNRER1RG5CQ1RvRUd3U3ZGV2NKcXhoMENhTkg1S2Zaa2RNalpHemtacFRIV2xpN1RXSE5Kci13VFh4YXQt?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "BioNTech's Promising Oncology Pipeline Is Now in Late-Stage Development", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNa3p3M1BIbFF1aS1yVlRpZDM3dGF4Nmh1UVRDbkh2azNtamI0SkdRcVBpcXZJcXJDZ3E4OXRWOGZ0cFBEb0pvYy14enU2WEg4VWtXdl9kMEx0elRpdjZONWsyTjRvQ1EyVnJTRGluaFlCVE96Zk5xbUgzbFd1V05nRUFjd1hPYm5wV1QtV3dGcEZlbmZ1S0xTRFhiUWJNTXFJaFU5WDBaS3FqTEloaWt0WEhsUHptVlhfd29FbjRZUQ?oc=5", "source_name": "Morningstar", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioNTech Stock Cratered 18% as Founders Exit to Launch New Venture", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPbVd5cnUwVjVxZUo5R291SENIUGVwSmpGcFhnM2gzRTRtUnhyeE1pRGxiWEE2MlJ6WE8wbnRkQUtYZS0zSUVWSE05cFFtOEJhQm5HWW9wSWwtS2hJSTByT1RDcHFWdmFnU0FLWGU0SWlxZkJ4X01ZZzJPbnBlSUo1eU4tOXhVNE9FSlFfcTVqTGdGQW5NelRRQ0xKLXd6UHk3bVh5QTRn?oc=5", "source_name": "TIKR.com", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Micron and BioNTech among market cap stock movers on Tuesday", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPQlpVczdpc0FCRTZFWi0wVlE5aHlINzB0MWtFWDgwVGR0bFc2aTVnV1owVURKeXh0NkgwODRQTS1SMnlkclk4dmZtbFhJY1hLMHNtV2dRbkZZZUZuTkxkU2xTaS15Z2EyWnUydjRQeG9ESVRYUXJHSTR1Y3VIRGVsTW1JQ2FBTGY3ejJuQW1sRnE4VVhQcXp0VWo2VjZjVkFOYWZoTk05V1p5UXRUdmZ5YmdCamNGcVZVbnVpRV9sdw?oc=5", "source_name": "Investing.com", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COVID-19 pioneers launch new mRNA firm, BioNTech targets 15 cancer trials", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOSHY3UmFxWUVSR0tJcDA3QVBDZ2lqaXh6SnlYS1JrT3ZYRFloVVNFaTRUMUNDaDBWcG5ONWhWS3JHUUQ2OHhSQzVVQ1BucDFfQVM2eEVRTjJGcTlMNWNveEM2anJjZ09hbFh2Y0hXWnA1QlRYTGJnVVF2Y0t2cC12STFGR2w5ekxkWC0tY2VPYmItd1JCM1VvakpSUmJ3SDUwTExXbjZMeXBGTVNjNkZRckdFMzBLNzF5cXFHZmkycUE?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why BioNTech Stock Is Getting Crushed Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxOUjhJOFpWdWtDaDFXeFVITWEtMFJyejVTaVp2WmhhTkx2XzhZOXFRUkk3Vk56RWVEY01qVUNRODNmdGVkUElIc0E4SkVHT1FGN2NVTXExMXkwcy10Ujh1NnVGUGNKRTdZTEVlYV9FMmlIbmt2bEprNjR0Zi1xRTdjWkVkbXc2MzlvaktZVDJpZw?oc=5", "source_name": "The Motley Fool", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioNTech SE's (NASDAQ:BNTX) Price Is Right But Growth Is Lacking After Shares Rocket 26%", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-28T08:00:00+00:00", "published_display": "28 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "BioNTech: The Market Is Paying Too Much For An Unproven Pipeline (NASDAQ:BNTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQZEpOTTk4bVhjb3NwM1E3c2tPSDZJN1VQUGFlTFBXUVczX1hQSjJhOEpjRk5CNE5MTVNLSzQwUmlzUG5IT08tQW9yOWFWcHV6emZFR3EyV1JBTDNCS0NHa3JHdmZuOXl4VHc4VlkyUEVkRFM2Q1NEel8xbkZUZFBYTXVUYXVXU3JkNXpkYnZnYlZVejR2UlV4SWZDSXJtMWoxSERoWjhkRQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-21T16:30:08+00:00", "published_display": "21 Jul 2026 16:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioNTech to Report Second Quarter 2026 Financial Results on August 4, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPaHdVbUkyeTd4anRvS3l1bUNnSExSZUxvUFNRREVKWTJPY1ZKX2phZXk5MEhRWE5aX0FTTkhvUkVJQ0lwWktrYUNmVnlmZVA2MjRXaGZSWTlnUWxtcWdhTmt5bGdpYmZENVhJMHE5RFgweldUT1Z6SERjRnNZeEFTVGVlTXZGbkJWLUZUYUF1VmpOenBhalFud0FPMC04U1BSMHZCYWJQM1Z2d1pmQUE?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-21T10:50:00+00:00", "published_display": "21 Jul 2026 10:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026", "summary": "BioNTech SE is scheduled to announce its second-quarter 2026 financial results on Tuesday, August 4, 2026. The company will also host a conference call and webcast on the same day at 8:00 a.m. ET to discuss the results and provide a corporate update. Investors and the public can ", "url": "https://www.manilatimes.net/2026/07/21/tmt-newswire/globenewswire/biontech-to-report-second-quarter-2026-financial-results-and-corporate-update-on-august-4-2026/2388277/amp", "source_name": "The Manila Times", "published_at": "2026-07-21T11:10:03", "published_display": "21 Jul 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioNTech sets Aug. 4 webcast for second-quarter update", "summary": "BioNTech SE (Nasdaq: BNTX) announced it will release its second-quarter 2026 financial results on Tuesday, August 4, 2026. On the same day, the company will host a conference call and webcast at 8:00 a.m. ET (2:00 p.m. CET) to discuss the results and provide a corporate update. I", "url": "https://www.stocktitan.net/news/BNTX/bio-n-tech-to-report-second-quarter-2026-financial-results-and-92avg8u2kvau.html", "source_name": "Stock Titan", "published_at": "2026-07-21T11:10:03", "published_display": "21 Jul 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioNTech SE (0A3M) to Announce Q2 2026 Financial Results and Host Investor Call on August 4", "summary": "BioNTech SE (Nasdaq: BNTX, 0A3M), a biopharmaceutical company, announced it will release its second-quarter 2026 financial results on Tuesday, August 4, 2026. Concurrently, the company will host a live conference call and webcast at 8:00 a.m. ET (2:00 p.m. CET) to discuss its qua", "url": "https://kalkinemedia.com/uk/news/announcements/biontech-se-0a3m-to-announce-q2-2026-financial-results-and-host-investor-call-on-august-4", "source_name": "Kalkine Media", "published_at": "2026-07-21T11:10:03", "published_display": "21 Jul 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "German biotech company behind COVID-19 vaccine took its first steps with help from the ERDF", "summary": "BioNTech, the German biotechnology company behind the Pfizer COVID-19 vaccine, received crucial early support from the European Regional Development Fund (ERDF) in 2009. This funding, totaling EUR 2.2 million, enabled the company to expand its research and development infrastruct", "url": "https://ec.europa.eu/regional_policy/projects/projects-database/german-biotech-company-behind-covid-19-vaccine-took-its-first-steps-with-help-from-the-erdf_en", "source_name": "European Commission", "published_at": "2026-07-19T19:13:12", "published_display": "19 Jul 2026 19:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioNTech (BNTX) Faces Fresh Patent Lawsuits, Is The Valuation Gap Too Wide?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-19T06:31:44+00:00", "published_display": "19 Jul 2026 06:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Pfizer-BioNTech COVID-19 Vaccine. Updated formulation keeps Comirnaty relevant", "summary": "The Pfizer-BioNTech COVID-19 Vaccine (Comirnaty) continues to be a key product for Pfizer, with updated formulations targeting current SARS-CoV-2 variants. The article details its development, regulatory approvals for various age groups, manufacturing and distribution challenges ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/the-pfizer-biontech-covid-19-vaccine-updated-formulation-keeps-comirnaty/69796860", "source_name": "ad-hoc-news.de", "published_at": "2026-07-18T14:58:45", "published_display": "18 Jul 2026 14:58", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors Are Reacting To BioNTech (BNTX) Expanded Global Patent Suits Targeting Its mRNA COVID-19 Vaccines", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-18T01:37:34+00:00", "published_display": "18 Jul 2026 01:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The BNT162b2 mRNA COVID-19 vaccine. Regulatory milestones shape BioNTech\u2019s core product", "summary": "BioNTech's BNT162b2 mRNA COVID-19 vaccine has evolved from emergency use to full approval in key markets, serving as both a primary and booster immunization. This product is a crucial driver for BioNTech's stock performance and forms the foundation for its broader mRNA portfolio,", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/the-bnt162b2-mrna-covid-19-vaccine-regulatory-milestones-shape/69785732", "source_name": "Ad Hoc News", "published_at": "2026-07-17T07:10:46", "published_display": "17 Jul 2026 07:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma, Genevant sue Pfizer, BioNTech Over Lipid Nanoparticle Patents", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/arbutus-biopharma-genevant-sue-pfizer-121613854.html", "source_name": "MT Newswires", "published_at": "2026-07-16T12:16:13+00:00", "published_display": "16 Jul 2026 12:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders", "summary": "Arbutus Biopharma, and its licensee Genevant, have initiated three international lawsuits against Pfizer and BioNTech for patent infringement related to their LNP technology used in COVID-19 vaccines. Arbutus has also received approximately $178 million from Moderna as part of a ", "url": "https://finance.yahoo.com/healthcare/articles/arbutus-initiates-international-patent-infringement-113000295.html", "source_name": "Market source", "published_at": "2026-07-16T11:41:56", "published_display": "16 Jul 2026 11:41", "sentiment": "negative", "sentiment_pct": 35, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The BNT162b2 COVID-19 Vaccine - BioNTech bets on updated protection", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQUFk5VjdYSHZ6MUhhNmYwNmFFRklWd0h0OVJqS08zNWY2NnFVTDVBaEJibWJNRFlteEtsSlo0LTBDX3NoSmZQMmhmUjBlVjhfZkR1anpBcHE0RVJJOXpNZkRfaE82UDAtY0YxMEs5M1VsM2Nwa3FjR3VMcWhVZkVWS3BBdm94ZmdHaUYzM3VkbDJ3Vmh1RC0xYWdqYjFDLXliOFhYdFVDVkVBbXMwaTB4OUNXQ0pxNHhXZmNxclJHOHNtQQ?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-16T10:34:50+00:00", "published_display": "16 Jul 2026 10:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(BNTX) as a Liquidity Pulse for Institutional Tactics", "summary": "This article provides an AI-driven analysis of BioNTech SE (NASDAQ: BNTX), highlighting a near-term weak sentiment that may lead to a resumption of long-term weakness. It details three institutional trading strategies\u2014Position Trading, Momentum Breakout, and Risk Hedging\u2014with spe", "url": "https://news.stocktradersdaily.com/news_release/16/BNTX_as_a_Liquidity_Pulse_for_Institutional_Tactics_071626040202_1784188922.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-16T03:41:57", "published_display": "16 Jul 2026 03:41", "sentiment": "negative", "sentiment_pct": 35, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cathie Wood's Ark Invest Sold $7.4 Million of BioNTech Stock", "summary": "Cathie Wood's Ark Invest recently sold over $7.4 million worth of BioNTech stock from its Ark Genomic Revolution ETF, leaving it with a minimal holding. This divestment follows BioNTech's underperformance, projected revenue decline due to reduced COVID-19 vaccine sales, consecuti", "url": "https://finance.yahoo.com/markets/stocks/articles/cathie-woods-ark-invest-sold-140200626.html", "source_name": "Market source", "published_at": "2026-07-14T14:02:02", "published_display": "14 Jul 2026 14:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The BNT162b2 vaccine - BioNTech SE bets on mRNA staying power", "summary": "BioNTech's BNT162b2 mRNA vaccine, co-developed with Pfizer, continues to be a cornerstone of the company's infectious disease portfolio, driving its stock price. The article highlights the vaccine's global reach, complex logistics, and evolving formulations targeting new variants", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/the-bnt162b2-vaccine-biontech-se-bets-on-mrna-staying-power/69758817", "source_name": "ad-hoc-news.de", "published_at": "2026-07-13T07:11:37", "published_display": "13 Jul 2026 07:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioNTech\u2019s Triple Transformation: Shuttering Plants, Losing Founders, and Banking on 15 Cancer Trials", "summary": "BioNTech is undergoing a significant corporate transformation, closing manufacturing plants and winding down a subsidiary, resulting in approximately 2,000 job cuts. This restructuring is occurring as the company's founders, Ugur Sahin and \u00d6zlem T\u00fcreci, prepare to depart to pursu", "url": "https://www.aktiencheck.de/news/Artikel-BioNTech_s_Triple_Transformation_Shuttering_Plants_Losing_Founders_and_Banking_on_15_Cancer_Trials-19923779", "source_name": "aktiencheck.de", "published_at": "2026-07-11T08:10:13", "published_display": "11 Jul 2026 08:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is BioNTech (BNTX) Undervalued As It Exits German Manufacturing Sites?", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/biontech-bntx-undervalued-exits-german-211008667.html", "source_name": "Simply Wall St.", "published_at": "2026-07-10T21:10:08+00:00", "published_display": "10 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioNTech (BNTX) Stock Could Be Overvalued After a 58% Five Year Slump", "summary": "BioNTech's stock has declined 57.5% over the past five years and is currently screening as overvalued based on market multiples, particularly its Price/Sales ratio of 7.3x compared to a fair implied P/S of 5.3x. Despite ongoing plans to reduce costs by exiting German manufacturin", "url": "https://finance.yahoo.com/markets/stocks/articles/biontech-bntx-stock-could-overvalued-121542659.html", "source_name": "Market source", "published_at": "2026-07-10T05:15:00", "published_display": "10 Jul 2026 05:15", "sentiment": "negative", "sentiment_pct": 27, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cathie Wood\u2019s ARK sells BioNTech and buys SpaceX stock", "summary": "Cathie Wood's ARK ETFs engaged in significant trading activity on July 8th, 2026. The firm sold over 78,000 shares of BioNTech and continued its trend of selling Roku and Advanced Micro Devices stock. Conversely, ARK made a substantial purchase of over 181,000 shares of Space Exp", "url": "https://www.investing.com/news/company-news/cathie-woods-ark-sells-biontech-and-buys-spacex-stock-93CH-4782834", "source_name": "Investing.com", "published_at": "2026-07-09T00:03:14", "published_display": "09 Jul 2026 00:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janet Markman: Excited to Become Director of Translational Sciences Oncology at BioNTech", "summary": "Janet Markman has been promoted to Director of Translational Sciences Oncology at BioNTech SE. She expressed her excitement and gratitude for the support and collaboration of her teams, acknowledging their role in her personal and professional growth. Markman is looking forward t", "url": "https://oncodaily.com/career/janet-markman-537837", "source_name": "Oncodaily", "published_at": "2026-07-08T14:41:14", "published_display": "08 Jul 2026 14:41", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioNTech SE strengthens its mRNA pipeline as investors watch global demand", "summary": "BioNTech SE is expanding its mRNA pipeline, focusing on oncology and infectious diseases, beyond its prominent COVID-19 vaccine success. The company aims to convert its scientific platform into sustainable revenue through various cancer vaccine approaches and strategic collaborat", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/biontech-se-strengthens-its-mrna-pipeline-as-investors-watch-global-demand/69717596", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T22:28:00", "published_display": "07 Jul 2026 22:28", "sentiment": "positive", "sentiment_pct": 69, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of BioNTech SE \u2013 NASDAQ:BNTX", "summary": "This article provides financial data for BioNTech SE (NASDAQ: BNTX), specifically its enterprise value to EBIT forward. It notes that the market for BNTX was closed with no trades. The information is presented by TradingView, sourcing data from ICE Data Services and FactSet Resea", "url": "https://www.tradingview.com/symbols/NASDAQ-BNTX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T11:39:01", "published_display": "04 Jul 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioNTech stock weighs pipeline and cash runway", "summary": "BioNTech's stock performance is heavily influenced by its clinical pipeline, partnership model, and the cash reserves accumulated from its COVID-19 vaccine sales. The company's ability to advance late-stage programs while maintaining significant R&D investment is crucial for its ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/biontech-stock-weighs-pipeline-and-cash-runway/69683070", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T20:41:07", "published_display": "03 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioNTech price exposed to negative pressures - Forecast today - 01-07-2026", "summary": "BioNTech SE (BNTX) experienced a decline in intraday trading due to resistance at its 50-day Simple Moving Average and extremely overbought momentum indicators. The primary short-term bearish trend remains dominant, and the forecast predicts further downside toward the $85.00 sup", "url": "https://www.economies.com/stocks/united-states-analysis/biontech-price-exposed-to-negative-pressures---forecast-today---01-07-2026-128122", "source_name": "Economies.com", "published_at": "2026-07-01T12:09:07", "published_display": "01 Jul 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioNTech SE (BNTX) Investor Outlook: Potential Upside of 33.49% Amidst Revenue Challenges", "summary": "BioNTech SE (BNTX) shows a potential upside of 33.49% with an average target price of $121.77, despite facing challenges such as negative revenue growth (-35.40%) and negative earnings per share. The company's robust pipeline in oncology and infectious diseases, particularly adva", "url": "https://www.directorstalkinterviews.com/biontech-se-bntx-investor-outlook-potential-upside-of-33-49-amidst-revenue-challenges/4121254952", "source_name": "DirectorsTalk Interviews", "published_at": "2026-06-29T10:11:00", "published_display": "29 Jun 2026 10:11", "sentiment": "positive", "sentiment_pct": 59, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vikas Sehdev: Starting a New Chapter as Senior Medical Science Liaison at BioNTech SE", "summary": "Vikas Sehdev has announced his departure from AstraZeneca after five years to join BioNTech SE as a Senior Medical Science Liaison focusing on Breast Cancer. He expressed gratitude for his time at AstraZeneca and enthusiasm for BioNTech's commitment to pioneering innovative thera", "url": "https://oncodaily.com/career/vikas-sehdev-530153", "source_name": "Oncodaily", "published_at": "2026-06-28T06:39:40", "published_display": "28 Jun 2026 06:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of BioNTech SE Sponsored ADR \u2013 BSESOF:22UA", "summary": "This article provides financial data for BioNTech SE Sponsored ADR (BSESOF:22UA) on TradingView, specifically focusing on its enterprise value to forward revenue. It presents a concise overview of the company's financial performance metrics for investors and analysts using the pl", "url": "https://www.tradingview.com/symbols/BSESOF-22UA/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T19:39:40", "published_display": "27 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioNTech SE Sponsored ADR Actuals & Estimates (NASDAQ:BNTX)", "summary": "This page on TradingView provides financial actuals and estimates for BioNTech SE (NASDAQ:BNTX). Users can explore reported financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation metrics, comparing actual results with av", "url": "https://www.tradingview.com/symbols/NASDAQ-BNTX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T17:10:35", "published_display": "27 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of BioNTech SE \u2013 NASDAQ:BNTX", "summary": "The article provides a financial metric, the \"Price to sales forward,\" for BioNTech SE (NASDAQ: BNTX). It presents a data table with \"Period,\" \"Value,\" \"Change,\" and \"Change %\" for this metric. The content highlights that the market was closed at the time of viewing, with no trad", "url": "https://www.tradingview.com/symbols/NASDAQ-BNTX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T11:10:35", "published_display": "27 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioNTech (BNTX) director Susanne Schaffert files Form 3 ownership", "summary": "BioNTech director Susanne Schaffert has filed a Form 3, an initial statement of beneficial ownership, identifying her as a director of BioNTech SE. This filing does not indicate any stock purchases, sales, or other share transactions, establishing a baseline of her holdings. The ", "url": "https://www.stocktitan.net/sec-filings/BNTX/form-3-bio-n-tech-se-initial-statement-of-beneficial-ownership-eb3813d8b73f.html", "source_name": "Stock Titan", "published_at": "2026-06-26T13:39:41", "published_display": "26 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioNTech (BNTX) director Low-Friedrich files Form 3 with no trades", "summary": "BioNTech director Iris Katharina Low-Friedrich has filed an initial Form 3, indicating her new director status at the company. The filing, however, reports no insider transactions or holdings, meaning there were no purchases, sales, or derivative securities beneficially owned at ", "url": "https://www.stocktitan.net/sec-filings/BNTX/form-3-bio-n-tech-se-initial-statement-of-beneficial-ownership-346e00ee72ae.html", "source_name": "Stock Titan", "published_at": "2026-06-26T13:39:41", "published_display": "26 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of BioNTech SE Sponsored ADR \u2013 BSESOF:22UA", "summary": "This article displays the \"Enterprise value to EBIT forward\" for BioNTech SE Sponsored ADR (BSESOF:22UA) on TradingView. It appears to be a stub or data point from a financial platform, showing that the market was closed at the time and no trades were recorded for this metric. Th", "url": "https://www.tradingview.com/symbols/BSESOF-22UA/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T11:39:41", "published_display": "26 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is BioNTech SE (BNTX) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPLVdXU1ZUU0l5OHQ2alNDMlMzZ1FmV1o4ZVl2emdyTTNiNEpLdHFsRzlBeml5V213ZG1BYkNhMl9CbDFrWF9jNWxEaVJ6Z2luQ1pBcEdtLVk1dHBoTmhUQzlRT0NJaHpwX3phc3F2UnZQRnhSU055UE5JUXIxWGN4bWMzOXZwSGUxVTlSRG8zMGo2aDdFZmZn?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioNTech (BNTX) and Bristol Myers Share New Results From ROSETTA Lung-02 Study", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNRk95NUc5WnY3OGZ0ZGlERk1CQkdBTnNkV1dLeUZvS08tM19UMTl6eHJDelRrcVF6aFFSRGJTNUNMUkZadDhOQnJ5WGtKU05wQmFrUTV0V1FqS0x6UEZlNmFORGlEd1ZXdDBOd0M0dnlianRWcFRoYUk5Y1YxbXhUMFZJWXYyWmhQeEJ6RGRNN3hpb1RPMEhZRlNEZW94eUk5aEpwSw?oc=5", "source_name": "Market source", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing BioNTech (BNTX) Valuation After Recent Share Price Weakness And Conflicting Growth Signals", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOYnBVSHhrVWxESEU5SlFmZmJ6cGhnNjBwVldSZnRUOXZZNTV4TDRSOXJHREM0TXR5dzhyd1pSVmZiVUh6aUxLZVI0R2pjRDJ6R1VwQUxnUDFFRjA0cTJKcTQ4YkgwUDZBazU1RjVaSjZ3OEZLUjVKUVhQblY3Q2Z3X3RMTDRoR1dYMTdzdzhoLUl4UXlLUm8zMkc1UUVrdGZSZXpYOVBnTkI?oc=5", "source_name": "Market source", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioNTech (BNTX) sets up USD 1.0B Nasdaq ADS repurchase program", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQYXhjMlNpUEpwdEduVmlNb2E0TGFsYXViZEYtVkFiUWprV0d6Ul91MFpPZXdNcUFRSXNyYXE2LWExWHU1THJXWDdzY2h3VHg2YjVIRVVUMXZxR3pCbUpmY2MxWGhiOGREYUdXekg4VDF6bVNPWnZmQXpiWGsxWUR0WHIzcVhuU3ZvQ1RvVHpWV29CcDc5dmFpRzNlajdtdVpLOGpHYXZRUkp3QUVFTHc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioNTech Stock Forecast | ASCO Oncology Data Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxQQThIWUU1Wm9DMWQ3eTJBeGFfYkoxMjZKUHFwdFdma3h1MW5DVnpuSEU1ckxhUU1rLTN0eFQzZG1yQ1NkOUN6b2txaUxGVWZiU3RLX0ZRelNBV2RBNDBDU0g2d3RpMGVZVEFpRFNKbHN4eDNxdkRxV0lrbjJTZWlOM19n?oc=5", "source_name": "Capital.com", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Experimental BioNTech lung cancer drug shows high responses in early trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOWHc1SXBERm82bTlyLXA4NTdQVWdobVljbGlQbm53aVVZVmJkRkhoeUZSR01xUmhtNjlEVVE1OXZHTS1wcmpHZ3hkcmFpaUJOQ0pXMWhfcjJsS2h2eXUtTWRjMDV2ZHJzOFlDajMyWE1pMjVpV25ITWh2bFphcHBlZGprWmR1dmdWb1BsRlZsYUJaaEJ6Qk1sQ1hKWUF2UUx3X0ptWGJJLVpxeHhwUHpmSG9UekJhNTRqbE9sa1NOVQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-30T07:00:00+00:00", "published_display": "30 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$1B BioNTech buyback runs to 2027 as company taps cash reserves", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQOHVHVDVBaU1mMmUtX2xGbXpQcnRnblktNzhURm1ONFcyRTF2bzRvMzdJTFFGcHlHMzZwUjhKM3pPUVhyM3dNZE90M3FNcUItd3dYRVFPSFktcVZ0eDZ4dVlUbXZVSWI2cXo4MkhSU0laVkJfWWFPbHk2am5UdzJYUWtRWkpneldZRGt5Rlg5Q3lUWWxfMXV3RTZB?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioNTech Q3 Earnings Review: Getting Into The Weeds With Bewildering Oncology Plans", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQcUxGa3RyTFlOTGNncnItMU5aMGhwNkFLWWxKMW9jeEJTSTVwLUJ3MzBwZTBwbk9nekxNYVVhNTQ2M2NMRzI5Q2xQS21KT0lzdUM5emRubkNJNkV4Smt4a2Rpd2Z6T0pWSjJtU2xiV0ZnWFdsaGYtSl83OWMtOWFEa2JFT3lZVHpQYTN6c1JpRWF4R3JwMWhyZkpQLWFFLW91X2xjMVlJZDV2SmN1YlBHZVBGblZienJlTTRmQzlRSXI?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BNTX Stock News: BioNTech Announces Layoffs as Covid-19 Revenue Slides", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNanFBQ290LVQ1eWhJUmE3TDI0RDJWTWgyeVRiV25nZncyekVKdnpIamhiMndBN2pySEF0LThuQnJDNTNHRy1EV01IREpZbTY3Z3kzb2NnU2xTaWVqU3VIbjNhOUhVdmlaSUtoSGUtNjB1NFFrTkpzTm5pYVd4TnRBMThXZjlKVXNMYmxaTDQzRloxVFRfbGNnejkxcHc5OE5B?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioNTech price receives positive push - Forecast today - 05-05-2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOOV9KWUJWZnpNdjNZT3ZjajBrMnV5MS1ENExTdXhGbGFJbTJWV3N1ZDBfcUZQalZabTBYdmVYUTFvNUJCX1B0eVZfaUgzZzhVSkd4RXJrdUFvWjh2MjhnWHc0ZmJYNDdYeS1qMVlJcFREV2xxbnJDSjIydldjZ05GSXROYkVMSmdQZ2lEbDhkM2R2MTZJY2gzcW9nbmhwOVpGSUVDZlVtM1h1SXdBbjlISEk5OUF6OWdUa1BLcnFBWUc0VnNheWQtekFB?oc=5", "source_name": "Economies.com", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioNTech (BNTX) Surges 6.1%: Is This an Indication of Further Gains?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxNWXhmaDZkdDJ4Ti1WSG9ReFZwT2JYX2xaVkFjQmNSRWhSakk2aTNtV1FsYXF6OENmRURlaTdfcURzREdNSDRnMXAzcVdWcmpIQjZvZDFsSEs3YS0zaVlRSHFJckNLZFF5QTZ3Ym9NRG1hTFE4LU1jSEMxcTZVZC1Ib2tvb2YzZFlmRzdtak11STZsREE?oc=5", "source_name": "Market source", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: Teleflex (TFX), Cigna (CI) and BioNTech SE (BNTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxNUVoyWXU2STdaQTRoeXNTZ2NoRG5TOElMQ3BZSjBfQ0J2SnNCU01jdXNFSDZuMXVNV3hlOVVKeHpxaDVKejZpUklzbE5UZnBjcUxCb080dHlueVpQRTNxX3FZR3NUTnhlbEtMWU91b1ZGZFRYbGZmdkR5NTJrQU9jUmxzYzg0dlJsaEQ0eDktWUJhRE1CeXhTWUVVY200SGF4a0tyTnhUTEhDcm9sVFZhODd3ckUzc0xUcjkyT3ExeW5udTJNRER1RG5CQ1RvRUd3U3ZGV2NKcXhoMENhTkg1S2Zaa2RNalpHemtacFRIV2xpN1RXSE5Kci13VFh4YXQt?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioNTech's Promising Oncology Pipeline Is Now in Late-Stage Development", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNa3p3M1BIbFF1aS1yVlRpZDM3dGF4Nmh1UVRDbkh2azNtamI0SkdRcVBpcXZJcXJDZ3E4OXRWOGZ0cFBEb0pvYy14enU2WEg4VWtXdl9kMEx0elRpdjZONWsyTjRvQ1EyVnJTRGluaFlCVE96Zk5xbUgzbFd1V05nRUFjd1hPYm5wV1QtV3dGcEZlbmZ1S0xTRFhiUWJNTXFJaFU5WDBaS3FqTEloaWt0WEhsUHptVlhfd29FbjRZUQ?oc=5", "source_name": "Morningstar", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioNTech Stock Cratered 18% as Founders Exit to Launch New Venture", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPbVd5cnUwVjVxZUo5R291SENIUGVwSmpGcFhnM2gzRTRtUnhyeE1pRGxiWEE2MlJ6WE8wbnRkQUtYZS0zSUVWSE05cFFtOEJhQm5HWW9wSWwtS2hJSTByT1RDcHFWdmFnU0FLWGU0SWlxZkJ4X01ZZzJPbnBlSUo1eU4tOXhVNE9FSlFfcTVqTGdGQW5NelRRQ0xKLXd6UHk3bVh5QTRn?oc=5", "source_name": "TIKR.com", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Micron and BioNTech among market cap stock movers on Tuesday", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPQlpVczdpc0FCRTZFWi0wVlE5aHlINzB0MWtFWDgwVGR0bFc2aTVnV1owVURKeXh0NkgwODRQTS1SMnlkclk4dmZtbFhJY1hLMHNtV2dRbkZZZUZuTkxkU2xTaS15Z2EyWnUydjRQeG9ESVRYUXJHSTR1Y3VIRGVsTW1JQ2FBTGY3ejJuQW1sRnE4VVhQcXp0VWo2VjZjVkFOYWZoTk05V1p5UXRUdmZ5YmdCamNGcVZVbnVpRV9sdw?oc=5", "source_name": "Investing.com", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COVID-19 pioneers launch new mRNA firm, BioNTech targets 15 cancer trials", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOSHY3UmFxWUVSR0tJcDA3QVBDZ2lqaXh6SnlYS1JrT3ZYRFloVVNFaTRUMUNDaDBWcG5ONWhWS3JHUUQ2OHhSQzVVQ1BucDFfQVM2eEVRTjJGcTlMNWNveEM2anJjZ09hbFh2Y0hXWnA1QlRYTGJnVVF2Y0t2cC12STFGR2w5ekxkWC0tY2VPYmItd1JCM1VvakpSUmJ3SDUwTExXbjZMeXBGTVNjNkZRckdFMzBLNzF5cXFHZmkycUE?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why BioNTech Stock Is Getting Crushed Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxOUjhJOFpWdWtDaDFXeFVITWEtMFJyejVTaVp2WmhhTkx2XzhZOXFRUkk3Vk56RWVEY01qVUNRODNmdGVkUElIc0E4SkVHT1FGN2NVTXExMXkwcy10Ujh1NnVGUGNKRTdZTEVlYV9FMmlIbmt2bEprNjR0Zi1xRTdjWkVkbXc2MzlvaktZVDJpZw?oc=5", "source_name": "The Motley Fool", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioNTech SE's (NASDAQ:BNTX) Price Is Right But Growth Is Lacking After Shares Rocket 26%", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-28T08:00:00+00:00", "published_display": "28 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 104, "total_relevant": 63, "sentiment_summary": {"positive": 14, "negative": 5, "neutral": 44, "score": 53, "total": 63, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 17.0, "count": 29}, {"event": "earnings", "label": "Earnings", "weight": 10.66, "count": 21}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.2, "count": 4}, {"event": "guidance", "label": "Guidance", "weight": 2.2, "count": 4}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "capital_return", "label": "Capital return", "weight": 1.1, "count": 2}], "positive_events": 14, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 91.48, "latest_week": "2026-07-17", "one_week_move": -0.0, "four_week_move": 0.6, "twelve_week_move": -13.3, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.064993, "market_dynamics_buy_signal": false, "relative_strength": -18.413434, "fair_value_gap": -9.9, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 53.5939, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.0% over one week, +0.6% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 51, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 14}, {"label": "Stock Titan", "count": 7}, {"label": "TradingView", "count": 6}, {"label": "simplywall.st", "count": 5}, {"label": "Seeking Alpha", "count": 2}, {"label": "ad-hoc-news.de", "count": 2}, {"label": "Ad-hoc-news.de", "count": 2}, {"label": "Investing.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 54}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 29}, {"label": "Earnings", "count": 21}, {"label": "Regulatory and legal", "count": 4}, {"label": "Guidance", "count": 4}, {"label": "Deals and strategy", "count": 2}, {"label": "Capital return", "count": 2}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "54", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "4", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-0.0% over one week, +0.6% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "BioNTech: The Market Is Paying Too Much For An Unproven Pipeline (NASDAQ:BNTX)"}], "updated_at": "2026-07-22T12:15:17.911806+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}